Emergent BioSolutions | EBS - 营业利润



金融业
股票价格
USD 6.44
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 355.5M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


营业利润 更改 日
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Akebia Therapeutics USD -5.45M 9.4M 2025-12
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 179.66M 67.06M 2026-09
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 39.84M 1.13M 2026-06
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Coherus Biosciences USD -39.08M 3.65M 2025-12
Emergent BioSolutions USD -218M 69.9M 2023-06
Exelixis USD 268.42M 20.01M 2026-09
Glaxosmithkline GBP 2.13B 166M 2026-09
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
Lonza CHF 673M 243M 2025-06
Merck USD 7.33B 6.49B 2026-09
Moderna USD -815M 573M 2026-06
Myriad Genetics USD -3M 20.3M 2025-12
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 343M 123.1M 2026-09
Pacira USD 9.96M 5.33M 2026-06
Pfizer USD 667M 4.32B 2026-06
PTC Therapeutics USD 148.98M 103.09M 2026-06
Sanofi EUR 4.72B 2.34B 2026-09
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
United Therapeutics USD 330.8M 5M 2026-06
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12